How to buy Auris Medical Holding stock (EARS)

Auris Medical Holding is a biotechnology business based in the US. Auris Medical Holding shares (EARS) are listed on the NASDAQ and all prices are listed in US Dollars. Auris Medical Holding employs 8 staff and has a trailing 12-month revenue of around $174,475.

Our top picks for where to buy Auris Medical Holding stock

Buy Auris Medical Holding stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Auris Medical Holding stock price (NASDAQ: EARS)

Use our graph to track the performance of EARS stocks over time.

Auris Medical Holding shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$3.25
200-day moving average more info button	$3.41
Wall St. target price	$14.95
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.48

Is it a good time to buy Auris Medical Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Auris Medical Holding financials

Revenue TTM	$174,475
Gross profit TTM	$174,475
Return on assets TTM	-21.99%
Return on equity TTM	-71.91%
Profit margin	0%
Book value	$1.47
Market Capitalization more info button	$39.2 million

TTM: trailing 12 months

Auris Medical Holding share dividends

We're not expecting Auris Medical Holding to pay a dividend over the next 12 months.

Have Auris Medical Holding's shares ever split?

Auris Medical Holding's shares were split on a 1:20 basis on 30 April 2019 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Auris Medical Holding shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Auris Medical Holding shares which in turn could have impacted Auris Medical Holding's share price.

Auris Medical Holding share price volatility

Over the last 12 months, Auris Medical Holding's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Auris Medical Holding's is 1.4048. This would suggest that Auris Medical Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Auris Medical Holding overview

Auris Medical Holding Ltd. , a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S. A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders.

Frequently asked questions

null
What percentage of Auris Medical Holding is owned by insiders or institutions?
Currently 5.445% of Auris Medical Holding shares are held by insiders and 5.585% by institutions. How many people work for Auris Medical Holding?
Latest data suggests 8 work at Auris Medical Holding. When does the fiscal year end for Auris Medical Holding?
Auris Medical Holding's fiscal year ends in December. Where is Auris Medical Holding based?
Auris Medical Holding's address is: Clarendon House, Hamilton, Bermuda, HM 11 What is Auris Medical Holding's ISIN number?
Auris Medical Holding's international securities identification number is: BMG0360L1000 What is Auris Medical Holding's CUSIP number?
Auris Medical Holding's Committee on Uniform Securities Identification Procedures number is: G07025201